48 institutions, one thesis: what their collective presence tells you about what the market is missing about InspireMD (NSPR)
When a single sophisticated investor puts money into a small company, it’s interesting.
When six specialized healthcare funds coordinate a $113.6 million financing round for a company that hasn’t yet received FDA approval, and then most of them come back for more after the approval arrives, that’s something different.
⚠️ Reader notice: The author holds a position or has active interest in NSPR at the time of writing. Nothing in this article constitutes financial advice. All analysis is based on publicly available information. Do your own due diligence.
That’s a consensus among people who spend their entire professional lives evaluating exactly this kind of asset.
InspireMD (NSPR) has 48 institutional investors with positions registered with the SEC. Most retail investors are aware of none of them. This article is about who they are, what they did, and what their collective presence implies about an asset that is currently trading at $1.65.
The Original Syndicate: Six Funds, $113.6 Million, Zero FDA Approval
In May 2023, InspireMD closed a private placement of up to $113.6 million.
At the time, InspireMD had approximately $7 million in annual revenue, no FDA approval, and a stock price that reflected deep uncertainty about whether the PMA process would succeed.
Six institutional investors, all specialized in healthcare, coordinated to commit up to $113.6 million to that company. The structure was milestone-based: an initial tranche upfront, with subsequent tranches tied to specific regulatory and commercial achievements.
Those six investors were:
- Marshall Wace
- OrbiMed
- Rosalind Advisors
- Nantahala Capital Management
- Soleus Capital Management
- Velan Capital Investment Management
With them, also certain members of InspireMD’s board.
Marshall Wace: The Fund That Keeps Coming Back
Marshall Wace is one of the most sophisticated hedge funds in the world, with approximately $70 billion in assets under management. They led the 2023 PIPE. They structured the milestone tranches. They tracked the FDA process. And then, in July 2025 — after the FDA approval — they came back. They participated in the follow-on PIPE at $2.42 per share alongside OrbiMed.
The current price is $1.65. Marshall Wace is sitting on a paper loss. They have not sold.
A $70 billion fund that runs long/short strategies does not hold losing positions out of inertia. They hold them when their ongoing analysis tells them the intrinsic value of the asset has not changed, only the market price has.
OrbiMed: The $18 Billion Specialist
OrbiMed manages approximately $18 billion exclusively in healthcare. They participated in the July 2025 PIPE at $2.42. Like Marshall Wace, they are currently below their cost basis. Like Marshall Wace, they have not sold.
OrbiMed lists InspireMD as an active portfolio holding on their website, not buried in a footnote, but acknowledged as a current investment. For a fund of their size and reputation, that public acknowledgment carries weight. They are not embarrassed by this position. They are standing behind it.
Rosalind Advisors: The Most Concentrated Bet In The Room
Of all the institutional investors in InspireMD’s cap table, Rosalind Advisors deserves the most attention, because their commitment to this thesis is the most concentrated of any institutional holder.
As of December 31, 2024, Rosalind held 9,933,964 shares of InspireMD, representing 9.90% of the entire company.
That alone would be significant. But the number that matters more is this: at that time, InspireMD represented 14.87% of Rosalind’s entire portfolio.
Nearly fifteen percent of everything Rosalind managed was in one position: InspireMD, an extraordinary concentration for a firm of their caliber.
Since then, Rosalind’s total AUM has grown substantially, which mechanically reduced NSPR’s portfolio weight to approximately 3.3%.
In other words, total exposure to InspireMD has not shrunk, it has grown.
As of the most recent filings, Rosalind holds 3,905,743 common shares plus 7,081,361 shares issuable upon exercise of warrants. This is a combined position of over 10.9 million shares, more than they held at year-end 2024. In Q3 2025 alone, they added 1.6 million shares. The conviction didn’t fade. The fund simply got bigger.
Nantahala, Soleus, Velan: The Healthcare Specialists
Nantahala Capital is a hedge fund known for concentrated positions in small and micro-cap companies with significant valuation disconnects. Their presence reflects exactly the kind of situation Nantahala pursues: a small company with a differentiated product, a clear regulatory pathway, and a market price that dramatically understates the asset’s potential.
Soleus Capital was founded by Guy Levy-Yurista, a former portfolio manager at SAC Capital’s healthcare team. Soleus focuses exclusively on healthcare and life sciences. Their participation reflects an independent evaluation of InspireMD’s clinical data and commercial opportunity by a team that spends every working day evaluating exactly these kinds of assets.
Velan Capital is known in the healthcare investment community for not being passive. They invest with a view, and they make that view known to management when appropriate. Their continued involvement suggests they are comfortable with how InspireMD is being managed.
The Broader Picture: 48 Registered Holders
Beyond the original syndicate, InspireMD has 48 institutional investors with positions registered with the SEC, holding a combined 23.46 million shares.
That list includes:
- Parkman Healthcare Partners: a boutique healthcare-focused investment firm that entered the cap table in September 2025, post-PIPE.
- Pura Vida Investments: specialists in small-cap biotech and medtech with a track record of identifying assets in the pre-catalyst phase.
- Ghisallo Capital Management: a multi-strategy hedge fund with a dedicated healthcare allocation.
- Standard Life Aberdeen: a global asset manager with over $500 billion in assets under management. The presence of a firm of this scale in a $121 million company is unusual.
The Number That Tells The Whole Story
48 institutions. 23.46 million shares. A coordinated $113.6 million financing in 2023 before FDA approval. A follow-on $58 million PIPE in 2025 after approval. The most concentrated single holder with nearly 15% of their entire portfolio in one position.
And a current market price of $1.65.
Each of these institutions has investment committees. Each has analysts who reviewed the clinical data, the competitive landscape, the regulatory pathway, the commercial opportunity, and the management team. Each made an independent decision to commit capital. None of them has sold at current prices.
The Honest Question This Raises
I want to be direct about what this article does and does not argue.
It does not argue that institutional investors are always right. They are not.
What it argues is simpler: when 48 institutions with domain-specific healthcare expertise, fiduciary obligations to their clients, and independent due diligence processes all reach the same conclusion about a $121 million company, and when the largest single holder puts nearly 15% of their entire portfolio into one position and continues to accumulate below cost, the burden of proof shifts.
The question is no longer ‘why would anyone invest in this?’
The question becomes ‘what does the market know that 48 institutions with combined assets in the hundreds of billions of dollars don’t?’
I’ve been looking for a compelling answer to that question. I haven’t found one.
Next in the series: ‘Why InspireMD (NSPR) May Be Getting So Little Promotion, And Why That Could Be The Most Bullish Signal Of All’
🟢 Disclosure: The author holds a position or has active interest in this name.
⚠️ I produce these analyses for my own enjoyment and because I’m always looking for new opportunities. I am not a financial professional, and I don’t have access to professional-grade tools or proprietary data. Everything here is built from publicly available information and my own reasoning — which means I can be wrong. I may not always see the full picture, and my views will change as new information emerges or as I come to understand data points I initially overlooked or underweighted. I only operate with cash positions — no leverage, no margin, no shorting. I never bet against the market or individual companies. My analysis reflects the company’s fundamentals, not its price action. The company is not its price, and the price is not the company. I express my own opinions. I am not receiving compensation to share this. I have no business relationship with any company whose stock is mentioned in this